Therefore, our findings uncover an intimate relationship between CypA and DDP/DTX resistance, which provides a preclinical rationale for targeting CypA as a therapeutic strategy for patients with DDP/DTX resistant NSCLC. The gene discussed is PPIA; the disease is non-small cell lung carcinoma.